Literature DB >> 11179303

Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli.

J C Paton1, T J Rogers, R Morona, A W Paton.   

Abstract

Gastrointestinal disease caused by Shiga toxin-producing Escherichia coli (STEC) is frequently complicated by life-threatening toxin-induced systemic sequelae, including the hemolytic uremic syndrome. We previously constructed a recombinant bacterium displaying a Shiga toxin receptor mimic on its surface which neutralized Shiga toxins with very high efficiency. Moreover, oral administration of the live bacterium completely protected mice from challenge with virulent STEC. In this study, we investigated the protective capacity of formaldehyde-killed receptor mimic bacteria, as these are likely to be safer for administration to humans. The killed bacteria completely protected STEC-challenged mice when administered three times daily; incomplete protection was achieved using two doses per day. Commencement of therapy could be delayed for up to 48 h after challenge without diminishing protection, depending on the virulence of the challenge strain. Thus, administration of this agent early in the course of human STEC disease may prevent progression to life-threatening complications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179303      PMCID: PMC98032          DOI: 10.1128/IAI.69.3.1389-1393.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2.

Authors:  T Takeda; K Yoshino; E Adachi; Y Sato; K Yamagata
Journal:  Microbiol Immunol       Date:  1999       Impact factor: 1.955

2.  Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7.

Authors:  E A Wadolkowski; J A Burris; A D O'Brien
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

Review 3.  Shiga and Shiga-like toxins.

Authors:  A D O'Brien; R K Holmes
Journal:  Microbiol Rev       Date:  1987-06

4.  Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.

Authors:  X Zhang; A D McDaniel; L E Wolf; G T Keusch; M K Waldor; D W Acheson
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

Review 5.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Molecular characterization of a Shiga toxigenic Escherichia coli O113:H21 strain lacking eae responsible for a cluster of cases of hemolytic-uremic syndrome.

Authors:  A W Paton; M C Woodrow; R M Doyle; J A Lanser; J C Paton
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

7.  The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. The R1 core-specific beta-glucosyltransferase provides a novel attachment site for O-polysaccharides.

Authors:  D E Heinrichs; J A Yethon; P A Amor; C Whitfield
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

8.  Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences.

Authors:  G D Armstrong; E Fodor; R Vanmaele
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

Review 9.  Infection by verocytotoxin-producing Escherichia coli.

Authors:  M A Karmali
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

Review 10.  Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.

Authors:  J C Paton; A W Paton
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more
  10 in total

Review 1.  Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections.

Authors:  Adrienne W Paton; Renato Morona; James C Paton
Journal:  Bioeng Bugs       Date:  2009-11-17

2.  Protection against Shiga-Toxigenic Escherichia coli by Non-Genetically Modified Organism Receptor Mimic Bacterial Ghosts.

Authors:  Adrienne W Paton; Austen Y Chen; Hui Wang; Lauren J McAllister; Florian Höggerl; Ulrike Beate Mayr; Lucy K Shewell; Michael P Jennings; Renato Morona; Werner Lubitz; James C Paton
Journal:  Infect Immun       Date:  2015-06-22       Impact factor: 3.441

3.  Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing.

Authors:  Laura Camarena; Vincent Bruno; Ghia Euskirchen; Sebastian Poggio; Michael Snyder
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

4.  Reduced virulence of an fliC mutant of Shiga-toxigenic Escherichia coli O113:H21.

Authors:  Trisha J Rogers; James C Paton; Hui Wang; Ursula M Talbot; Adrienne W Paton
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

5.  Specific detection of Salmonella enterica and Escherichia coli strains by using ELISA with bacteriophages as recognition agents.

Authors:  E Galikowska; D Kunikowska; E Tokarska-Pietrzak; H Dziadziuszko; J M Loś; P Golec; G Węgrzyn; M Loś
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-15       Impact factor: 3.267

6.  Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge.

Authors:  Ulrike Beate Mayr; Pavol Kudela; Alena Atrasheuskaya; Eugenij Bukin; Georgy Ignatyev; Werner Lubitz
Journal:  Microb Biotechnol       Date:  2011-11-22       Impact factor: 5.813

Review 7.  Verotoxin Receptor-Based Pathology and Therapies.

Authors:  Clifford Lingwood
Journal:  Front Cell Infect Microbiol       Date:  2020-03-31       Impact factor: 5.293

8.  φYeO3-12 phage tail fiber Gp17 as a promising high specific tool for recognition of Yersinia enterocolitica pathogenic serotype O:3.

Authors:  Karolina Filik; Bożena Szermer-Olearnik; Joanna Niedziółka-Jönson; Ewa Roźniecka; Jarosław Ciekot; Anna Pyra; Irwin Matyjaszczyk; Mikael Skurnik; Ewa Brzozowska
Journal:  AMB Express       Date:  2022-01-06       Impact factor: 3.298

9.  Probiotics and gastrointestinal infections.

Authors:  Robert A Britton; James Versalovic
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-02-04

10.  Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.

Authors:  Shannon J Hostetter; Amy F Helgerson; James C Paton; Adrienne W Paton; Nancy A Cornick
Journal:  BMC Res Notes       Date:  2014-06-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.